Fig. 3From: CDH22 hypermethylation is an independent prognostic biomarker in breast cancerClinical value of CDH22 hypermethylation in BC. Significant associations between CDH22 hypermethylation in all three examined CpG sites and progression-free survival and overall survival were found in our series of BC casesBack to article page